This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The trial will evaluate the outcomes of therapy provided with the FARAPULSE PFA System versus AADs, including device-or procedure-related adverse events, the rates of freedom from AF, atrialflutter, or atrial tachycardia, as well as AF burden – a measurement of the amount of AF an individual experiences. Circulation.
ABSTRACT Background Atrialfibrillation and atrialflutter are relatively rare in young people and the incidence of thromboembolic complications is unknown. These issues contribute to the limited utility of present guidelines regarding anticoagulation in this population.
Atypical AtrialFlutter (AAFL) prevalence is increasing due to the escalating AtrialFibrillation (AF) ablations and cardiac surgeries. We wanted to explore the outcome of the AAFL ablation, considering the recent changes in mapping and ablation.
She also has a hx of paroxysmal atrialfibrillation and is on oral anticoagulant treatment. The ECG was interpreted as showing atrialflutter with 2:1 conduction. The heart rate could be compatible with that of a 2:1 conducted atrialflutter. The last echocardiography 12 months ago showed HFmrEF.
Abstract Introduction Atrialfibrillation and atrialflutter originating from the donor s heart is a commonly reported complication post heart transplant. Case A 47-year-old male presented with atrial tachycardia 6 months post heart transplant.
intermittent) atrialfibrillation (AF) and is a unique new alternative to standard-of-care thermal ablation treatment. intermittent) atrialfibrillation (AF) and is a unique new alternative to standard-of-care thermal ablation treatment. said Nick Spadea-Anello, president, Electrophysiology, Boston Scientific. "The
Procedures were most commonly for atrialfibrillation (52.4%), atrialflutter (10.9%), and atrioventricular nodal re-entrant tachycardia (10.1%). Results 1089 patients were included: MC 718 (65.9%); Fo8 HT 105 (9.6%); Fo8 MOD 266 (24.4%). 01; minor: MC 16.5%, Fo8 HT 12.0%, Fo8 MOD 7.4%, p =.002).
Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:Inflammation may promote atrialfibrillation (AF) recurrence after catheter ablation. mg twice daily or placebo for 10 days. mg twice daily or placebo for 10 days. The first dose of the study drug was administered within 4 hours before ablation.
Abstract Introduction The use of flecainide and propafenone for medical cardioversion of atrialfibrillation (AF) and atrialflutter/intra-atrial reentrant tachycardia (IART) is well-described in adults without congenital heart disease (CHD).
FAAM ablation successfully decreased the recurrence rate of atrial tachyarrhythmia compared with conventional non-PV foci ablation. Abstract Introduction Treatment of recurrent atrialfibrillation (AF) is sometimes challenging due to non-pulmonary vein (PV) foci. The RHYTHMIA system was used to perform all the procedures.
Although the QDOT MICRO™ Catheter was mainly designed for pulmonary vein isolation (PVI) its versatility to treat atrialfibrillation (AF) and other types of arrhythmias was recently evaluated by the FAST and FURIOUS study series and other studies and will be presented in this article.
Abstract Background Dofetilide is a class III antiarrhythmic agent approved for the treatment of atrialfibrillation and atrialflutter. Given the efficacy of other class III agents, it has been used off-label for the treatment of premature ventricular complexes (PVCs) and ventricular tachycardias (VTs).
ABSTRACT Introduction The safety and efficacy of paroxysmal atrialfibrillation (PAF) ablation with the HELIOSTAR multielectrode radiofrequency (RF) balloon catheter have been demonstrated in European studies; data from elsewhere are lacking. Central Illustration. Image is courtesy of Biosense Webster, Inc., All rights reserved.
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech , today announced European CE mark approval of the VARIPULSE Platform for the treatment of symptomatic drug refractory recurrent paroxysmal atrialfibrillation ( AF ) using pulsed field ablation (PFA). AtrialFibrillation. Circulation.
There is atrial activity before every QRS, but that activity has negative polarity, so it is not sinus rhythm. There are clearly no flutter waves, so it is not atrialflutter (a "macro-reentrant" atrial tachycardia) Is it AVNRT originating at the superior pole of the AV node, resulting in a retrograde P-wave before the QRS?
ABSTRACT Typical atrialflutter (AFL), defined as cavotricuspid isthmus (CTI)-dependent macro-re-entrant atrial tachycardia, often causes debilitating symptoms, and is associated with increased incidence of atrialfibrillation, stroke, heart failure, and death.
Electrophysiologic studies were performed in selected patients only as clinically appropriate. Arrhythmias as a cause of syncope were diagnosed by cardiac monitoring or electrophysiologic testing. Holter monitoring, or intracardiac electrophysiologic studies, alone or in combination (diagnostic yields, 5% to 35%).
ABSTRACT Introduction Freedom from recurrences of atrial tachyarrhythmia (ATA) is suboptimal after pulmonary vein isolation (PVI) in patients with persistent atrialfibrillation (PsAF).
ABSTRACT Background Different ablation strategies have been developed for persistent atrialfibrillation (PeAF), but early management is still controversial. In the clinical setting of PeAF, the safety and efficacy of early Marshall plan have not yet been fully studied.
The Affera system was designed to address procedural challenges faced by the electrophysiology community while maintaining a high standard of safety and efficacy for patients. tim.hodson Wed, 10/30/2024 - 13:42 Oct. With this approval, Medtronic now offers two PFA technologies available for patients with Afib.
Cardioversion is most beneficial for reentrant arrhythmias ( e.g. VT, atrialflutter, AVNRT, atrialfibrillation) because it terminates the reentry circuit. Atrial tachycardia can occasionally be due to reentry, but reentrant circuits usually have a more stable cycle length without so much beat to beat variability.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
115 
Let's personalize your content